Fueled by deep scientific expertise built over decades of research, Advantx Pharmaceuticals is advancing a pipeline of therapeutic candidates for a number of rare and chronic diseases. Advantx fully owns all listed assets, with worldwide rights and full patent protection until 2041.

ADV502 Program Details

The ADV502 candidate is a novel (NCE), orally-administered, brain-penetrating, pharmaceutical-grade small molecule precisely designed to selectively bind specific regions of the SigmaR1 protein complex and partially modulate µ-opioid receptors (MOR).
Learn more

Polysubstance Use Disorder
*Patent until 2035 (compound) and 2037 (salt)

Preparing IND submission for Phase Ib/2a
ADV462 Program Details

The candidate ADV462 is a novel (NCE), orally-administered, brain-penetrating, pharmaceutical-grade small molecule precisely designed to selectively bind specific regions of the Sigma-2 protein complex inside neuronal cells and regulate cellular damage response.
Learn more

AD in Down syndrome

Preparing IND submission for Phase I
ADV127 Program Details

The ADV127 candidate is a novel (NCE), orally-administered, brain-penetrating, pharmaceutical-grade small molecule precisely designed to selectively bind specific regions of the SigmaR1 protein complex inside neuronal cells and modulate an agonist activation to restore cellular homeostasis.
Learn more

Fragile X Syndrome

Preclinical Validation
ADV368
ADV368 Program Details

The candidate ADV368  is a novel (NCE), orally-administered, brain-penetrating, pharmaceutical-grade small molecule precisely designed to selectively bind to specific regions of SigmaR1 and SigmaR2 proteins within neuronal cells to stimulate neurogenesis, reduce neuroinflammation and regulate the response to cell damage.
Learn more

ALS

Preclinical Validation

Advantx Pharmaceuticals Inc, is advancing with accelerated biomarker-driven clinical development a comprehensive pipeline of multi-backed, pharmaceutical-grade compounds based on new molecular entities designed in-house with our proprietary Sigma platform to address with genetic precision the unmet medical needs and limited treatment options for patients suffering from prevalent or rare neurodegenerative, neuropsychiatric, and neuropathic disorders. Our pipeline initially consists of nine clinical and preclinical phase mono-therapeutic programs and has the potential to expand into new indications and therapeutic areas, given the enormous potential of the unique Sigma chaperone receptors, pluripotent regulators of the living system.
Learn more